Halberd Corporation (OTC: HALB) detailed the latest NeuroSense AI metrics – its integrated, voice-based behavioral intelligence platform. This milestone enables brief voice samples to generate ...

Halberd demonstrated elimination of the final two of the "Top Ten" antigens linked to neurodegenerative diseases. Halberd demonstrated that its antigen elimination process is able to selectively ...

JACKSON CENTER, PA / ACCESSWIRE / September 27, 2022 / Halberd Corporation (OTC PINK:HALB) entered into a strategic alliance with AI Longevity, Inc. and Stem of Hope to form a strategic alliance as a ...

A Major Step Towards the Elimination of Multiple Infectious Diseases and Possible Treatment for Alzheimer's Disease/PTSD/CTE Felder continued, "Our method envisions utilizing a dialysis variation in ...

Mississippi State University (MSU) is well on their way in testing Halberd's patent-pending nasal spray to mitigate the neurological effects resulting from traumatic brain injuries (TBI). By directly ...

JACKSON CENTER, PA / ACCESSWIRE / October 18, 2022 / Halberd Corporation (OTC PINK:HALB) has successfully eliminated various antibiotic resistant bacteria from buffer solution in-vitro through the use ...

New milestone delivers repeatable stress and behavioral metrics, AI-assisted summaries, and longitudinal per-subject tracking - on the same pipeline headed for wearable check-ins MELBOURNE, Fla., June ...